Effects of Lovastatin on the Pharmacokinetics of Verapamil and its Active Metabolite, Norverapamil in Rats: Possible Role of Pglycoprotein Inhibition by Lovastatin

다국어 초록 (Multilingual Abstract)

This study was to investigate the effect of lovastatin on the bioavailability or pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. The pharmacokinetic parameters of verapamil and norverapamil in rats were measured after the oral administration of verapamil (9 mg/kg) in the presence or absence of lovastatin (0.3 or 1.0 mg/kg). The pharmacokinetic parameters of verapamil were significantly altered by the presence of lovastatin compared to the control group (given verapamil alone). The presence of lovastatin
significantly (p < 0.05, 0.3 mg/kg; p < 0.01, 1.0 mg/kg) increased the total area under the plasma concentration-time curve (AUC) of verapamil by 26.5-64.8%, and the peak plasma concentration (Cmax) of verapamil by 34.1-65.9%. Consequently, the relative bioavailability (R.B.) of verapamil was increased by 1.27- to 1.65-fold than that of the control group. However, there
was not significant change in the time to reach the peak plasma concentration (Tmax) and the terminal half-life (t1/2) of verapamil in the presence of lovastatin. The AUC and Cmax of norverapamil were significantly (p < 0.05) higher than those of presence of 1.0 mg/kg of lovastatin compared with the control group. However, there was no significant change in the
metabolite-parent ratio (M.R.) of norverapamil in the presence of lovastatin. The presence of lovastatin significantly enhanced the oral bioavailability of verapamil. The enhanced oral bioavailability of verapamil may be due to inhibition both of the CYP3A-mediated metabolism and the efflux pump P-glycoprotein (P-gp) in the intestine and/or in liver by the presence of
lovastatin.

참고문헌 (Reference)

1 Cummins, C. L., "Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4" 300 : 1036-1045, 2002

2 Benet, L. Z., "Transporterenzyme interactions: implications for predicting drugdrug interactions from in vitro data" 4 : 393-398, 2003

3 Lewis, G. R., "The treatment of hypertension with verapamil" 87 : 351-354, 1978

4 Eichelbaum, M., "The metabolism of DL-[14C]verapamil in man" 7 : 145-148, 1979

5 Mousa, O., "The interaction of diltiazem with simvastatin" 67 : 267-274, 2000

6 Azie, N. E., "The interaction of diltiazem with lovastatin and pravastatin" 64 : 369-377, 1998

7 Gould, B. A., "The 24-hour ambulatory blood pressure profile with verapamil" 65 : 22-27, 1982

8 Fleckenstein, A., "Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle" 17 : 149-166, 1977

9 Döppenschmitt, S., "Role of P-glycoprotein mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein" 88 : 1067-1072, 1999

10 Saitoh, H., "Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine" 12 : 1304-1310, 1995

11 Schomerus, M., "Physiological disposition of verapamil in man" 10 : 605-612, 1976

12 Eichelbaum, M., "Pharmacokinetics of (+)-, (−)- and (±)-verapamil after intravenous administration" 17 : 453-458, 1984

13 Zhang, Y., "Overlapping substrate specificities of cytochrome P450 3A and Pglycoprotein for a novel cysteine protease inhibitor" 26 : 360-366, 1998

14 Tobert, J. A., "Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors" 2 : 517-526, 2003

15 Khandwala, H. M., "Lipid lowering inefficacy of high-dose statin therapy due to concurrent use of phenytoin" 99 : 1385-1387, 2006

16 Neuvonen, P. J., "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid" 60 : 54-61, 1996

17 Wang, E., "HMG-CoA reductase Inhibitors (statins) characterized as direct inhibitors of P-glycoprotein" 18 : 800-806, 2001

18 Choi, D. H., "Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats" 29 : 45-50, 2008

19 Choi, D. H., "Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil" 64 : 445-449, 2008

20 Wolozin, B., "Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors" 57 : 1439-1443, 2000

21 Halpin, R. A., "Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human" 21 : 1003-1011, 1993

22 Kubota, T., "Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors" 67 : 2175-2186, 2004

23 Mason, R. P., "A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence" 5 : 489-501, 2005

24 Johnson, B. M., "A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum" 305 : 151-158, 2003